AZ's Brilinta Takes Next Step, Gains FDA Approval For Extended Use
This article was originally published in Scrip
The US FDA has approved AstraZeneca PLC's oral antiplatelet treatment, Brilinta (ticagrelor), in a new indication, allowing the product to be used as a longer term therapy for patients with acute coronary syndrome (ACS).
You may also be interested in...
Ten years at AstraZeneca PLC have prepared US President and Executive Vice President of North America Paul Hudson for his next C-suite job, but unfortunately for his current employer that gig is with a major competitor – Novartis AG.
In this latest instalment of the In Vivo podcast Daniel Lofaso, CEO of Digital Elevator, talks about the common mistakes biotech companies make when trying to build their brand, how to connect with varied audiences and key trends the industry should keep track of in digital marketing.
Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead.